Диссертация (1139475), страница 36
Текст из файла (страница 36)
– P. 63 - 71.416. O’Donnell M. R., Padayatchi, N., Master, I., Osburn, G. & Horsburgh, C. R.Improved early results for patients with extensivelydrug-resistant tuberculosisand HIV in South Africa. J Tuberc 13, 855–861 (2009).417. Ohno H., Koga H., Kohgo S.. Genetic mechanisms of drug-resistance// Kekkaku. - 1998. - Vol. 73. - № 11. - P.
657-663.418. Okur E., Kir A., Halezeraglu S., Levent Alpay A., Atasalihi A. Pleural tentfolowing upper lobectomies or bilobectomues of the lung to prevent residual airspace and prolonged air leak // Eur. J. cardiothorac. Surg. – 2001. –Vol.
20. – P.1012-1015.419. Oladimeji O. et al. Intensive-phase treatment outcomes among hospitalizedmultidrug-resistant tuberculosis patients: results froma nationwide cohort in243Nigeria.PLoSONEElectronResour.9,e94393,https://doi.org/10.1371/journal.pone.0094393 (2014).420. Oliveira O., Gaio, R., Villar, M. & Duarte, R. Predictors of treatment outcomein multidrug-resistant tuberculosis in Portugal. EurRespir J. 42, 1747–1749(2013).421.
Oppolzer W., Prelog, V. and Sensi P. Konstitution des Rifamycins B undverwandter Rifamycine // Experientia. – 1964. - Vol. 20. – P. 336 - 339.422. Orki A, Kosar A, Demirhan R, Saygi A, Arman B. The value of surgicalresection in patients with multidrug resistant tuberculosis. Thorac CardiovascSurg 2009; 57: 222–25.423. Park S.K., Kim C.T., Song S.D. Outcome of chemotherapy in 107patients with pulmonary tuberculosis resistant to isoniazid and rifampin // Int. J.Tuberc. Lung Dis. - 1998.
- Vol. 2. - № 11. - P.877-874.424. Park S.K., Lee C.M., Heu J.P., Song S.D. A retrospective study for theoutcome of pulmonary resection in 49 patients with multidrug-resistanttuberculosis // Int. J. Tuberc. Lung Dis. – 2002. - Vol. 6. - №2. – Р.143-149.425. Park S.K, Kim JH, Kang H, Cho JS, Smego RA Jr. Pulmonary resectioncombined with isoniazid- and rifampin-based drug therapy for patients withmultidrug-resistant and extensively drug-resistant tuberculosis. Int J Infect Dis2009; 13: 170–75.426. Park M.
M., Davis, A. L., Schluger, N. W., Cohen, H. & Rom, W. N.Outcomeof MDR-TB patients, 1983–1993. Prolonged survivalwith appropriate therapy. JRespir. 153, 317–324 (1996).427. Pazarli P., Duman, D. Y., Mocin, O. Y. & Karagoz, T. The effect of smokingon treatment outcome of multidrug-resistant tuberculosis.Turk Toraks Derg. 14,93–97 (2013).428.
Pestova E. et al. Intracellular targets of moxifloxacin: a comparison withother fluoroquinolones // Peterson Journal of Antimicrobial Chemotherapy. 2000. - Vol. 45. - №5. - P.583–590.244429. Petrov D., Stanoev V., Manolov E. et al. Pleural tent after high partical lungresection-prospective randomized research // Khirurgia (Sofia). – 2003.
– Vol.59. - №5. – P. 11-14.430. Pfaller,M.A.Applicationofnewtechnologytothedetection,identification,and antimicrobial susceptibility testing of Mycobacteria / M.A.Pfaller // Am. J.Clin. Pathol. – 1994. – N. 101. – P. 329-337.431. Phuong N. T. et al. Management and treatment outcomes of patients enrolledin MDR-TB treatment in Viet Nam. Public HealthAction. 6, 25–31 (2016).432. Picciocchi A., Granone P., Margaritora S., Cesario A., Galetta D. Surgicalmanagement of pulmonary tuberculosis // Rays. – 1998. - Vol.
23. – №1. – Р.193-202.433. Pomerantz B.J., Cleveland J.C. Jr., Olson H.K. et al. Pulmonaryresection for multi-drug resistant tuberculosis // J. Thorac. Cardiovasc. Surg. 2001. - Vol. 121. - № 3. - P. 448-453.434. Pomerantz M., Brown J.M. Surgery in the treatment of multidrugresistant tuberculosis // Clin. Chest Med. - 1997. - Vol. 18. -№ 1. -P.123-130.435. Pym Alexander S., Diacon Andreas H., Tan Shen-Jie et al.
Bedaquiline inthe treatment of multidrug- and extensively drug-resistant tuberculosis //European Respiratory Journal. - 2016. – Vol. 47. - №2. – P. 564-574.436. Quitugua T.N., Seaworth B.J., Weis S.E. Transmission of drug-resistanttuberculosis in Texas and Mexico // J. of Clin. Microbiology. - 2002. - 40. - №8. - P. 2716-2724.437. Ramaswamy S. Molecular genetic basis of antimicrobial agent res istance inM. tuberculosis: 1998 update / S. Ramaswamy, J. Musser // J.
Tuberc. LungDis. – 1998. – Vol. 79. – N. 1. – P. 3 – 29.438. Rattan A. Multidrug - resistant M. tuberculosis: molecular perspectives /A. Rattan, A. Kalia, N. Ahmad // Emerging Infectious Dis. – 1998. – Vol. 4. –N. 2. –P. 35 – 38.245439. Raviglione M.C., Gupta R., Dye CM. et al. The burden of drug-resistanttuberculosisand mechanismsfor itscontrol // New vistasintherapeutics, from drug design to gene therapy: drug-resistant tuberculosis,from molecules to macro-economics. - 2001. - Vol. 953.
- P. 88-97.440. Riquet M., Souilamas R. Surgery of thoracic and pulmonary tuberculosisand the sequelae of its treatment in adults // Rev. Mal. Respir. – 1997. - Vol. 14.– Suppl. 5. – Р. 105-120.441. Rist N., Grumbach F., Libermann D. F, Libermann D. Experiments on theantituberculous activity of alpha-ethylthioisonicotinamide// Am. Rev.
Respir.Dis. – 1959. – Vol. 79. – P. 1-5.442. Robinson T.D., Barnes D.J. A role for surgery in the management of multidrug-resistant tuberculosis (MDRTB) // Aust. N. Z. J. Med. – 1998. - Vol. 28 № 4. - Р.473-474.443. Russell R Kempker, Sergo Vashakidze, Nelly Solomonia, et al. Surgicaltreatment of drug-resistant tuberculosis. Lancet Infect Dis 2012;12: 157–66.444. Sagwa E. The burden of adverse events during treatment of drug-resistanttuberculosis in Namibia / E. Sagwa, B. van Wyk, A. K. Mantel-Teeuwisse, J. P.Musasa, S. Pal, P. Dhliwayo //Southern Med Review. ‒ 2012. ‒ Vol.
5. ‒ №1. ‒P. 6–13.445. Sasano S., Yamamoto H., Otsuka T., Fujita A., Onuki T., Nitta S. Surgicalmanagement of multidrug-resistant tuberculosis // Jpn. J. Thorac. Cardiovasc.Surg. – 2001. - Vol. 49. - №2. – Р.141-144.446. Satti H. et al. Outcomes of multidrug-resistant tuberculosis treatment withearly initiation of antiretroviral therapy for HIV coinfectedpatients in Lesotho.PLoSONEElectronResour.7,e46943,https://doi.org/10.1371/journal.pone.0046943 (2012).447. Saugman C.
Uber die Anwendung des Kiinstlichen Pneumothorax in derBehandlung der Lungentuberkulose. Z Tuberk 1908; 12:1-20.448. Schluger N.W. The impact of drug resistance on the global tuberculosisepidemic // Pap. 4th Annu. Meet. Int. Union Against Tubercle Lung Disease. N.246Amer. Reg.
«TB and HIV, Applying Adv.», Chicago, III., 25–27 Febr., 1999 //Int. J. Tubercle Lung Disease. – 2000. – Vol. 4, № 2, Suppl. 1. – С.71-75.449. Scorpio, A., Zhang, Y. Mutations in pncA, a gene encodingpyrazinamidase/nicotinamidase, cause resistance to the antituberculous drugpyrazinamide in tubercle bacillus // Nat. Med. - 1996. – Vol. 2. – P. 662 – 667.450. Seddon, J. A., Hesseling, A. C., Willemse, M., Donald, P. R. & Schaaf, H. S.Culture-confirmed multidrug-resistant tuberculosis inchildren: clinical features,treatment, and outcome. Clin Infect Dis.
54, 157–166 (2012).451. Segala Elena, Sougakoff Wladimir, Nevejans-Chauffour Aurelie, JarlierVincent, Petrella Stephanie. New Mutations in the Mycobacterial ATPSynthase: New Insights into the Binding of the Diarylquinoline TMC207 to theATP Synthase C-Ring Structure // Antimicrobial Agents and Chemotherapy. 2012. – Vol. 56.
- № 5– P. 2326-2334.452. Sensi P., Margalith P., Timbal M.T. // Farmaco. – 1959. – Vol. 14. – P. 146147.453. Shah N. S. et al. Extensively drug-resistant tuberculosis in the United States,1993–2007. JAMA. 300, 2153–2160 (2008).454. Shi D., Li L., Zhao Y., Jia Q., Li H., Coulter C., Jin Q., Zhu, G.Characteristics of embB mutations in multidrug-resistant Mycobacteriumtuberculosis isolates in Henan // China.
J. Antimicrob. Chemother. – 2011. –Vol. 66. – P. 2240 - 2247.455. Shin S. S. Adverse reactions among patients being treated for MDR-TB inTomsk, Russia / S.S. Shin, A.D. Pasechnikov, I.Y. Gelmanova, G.G. Peremitin,A.K. Strelis, S. Mishustin, A. Barnashov, Y. Karpeichik, Y.G. Andreev, V.T.Golubchikova, T.P. Tonkel, G.V.
Yanova, A. Yedilbayev, M.L. Rich, J.S.Mukherjee, J.J. Furin, S. Atwood, P.E. Farmer, S. Keshavjee // Int J TubercLung Dis. ‒ 2007. ‒ Vol. 11. ‒ №12. ‒ Р. 1314–1320.456. Shin S. S. et al. Treatment outcomes in an integrated civilian and prisonMDR-TB treatment program in Russia //Int J Tuberc Lung Dis. 2006 Oct;10(10) : 1183.247457. Shiraishi Y, Katsuragi N, Kita H, Toishi M, Onda T. Experience withpulmonary resection for extensively drug-resistant tuberculosis. InteractCardiovasc Thorac Surg 2008; 7: 1075–78.458.
Shiraishi Y, Katsuragi N, Kita H, Tominaga Y, Kariatsumari K, Onda T.Aggressive surgical treatment of multidrug-resistant tuberculosis. J ThoracCardiovasc Surg 2009; 138: 1180–84.459. Shiraishi Y., Nakajima Y., Katsuragi N., Kurai M., Takahashi N.Resectional surgery combined with chemotherapy remains the treatment ofchoice for multidrug-resistant tuberculosis // J. Thorac Cardiovasc. Surg. –2004.
- Vol. 128. - №4. – Р. 523-528.460. Shitrit D., Bendayan D., Saute M., Kramer MR. Multidrug resistanttuberculosis following lung transplantation: treatment with pulmonary resection// Thorax. – 2004. - Vol. 59. - №1. – Р. 79-80.461. Sipit T., Calisir H., Tastepe J. et al. Surgical approach to multiresistantpulmonary tuberculosis in Ankara Turkey // Surgery of tuberculosis. AbstractsMoscow international conference. – 1997. – P. 125-126.462. Snider D.E. The global threat of drug-resistant tuberculosis / D.E.
Snider //N. Engl. J. Med. – 1998. – N. 338. – P. 1689-1690.463. Solotorovsky M., Gregory F.J., Isonson E.J. et al. // Antimicrob. AgentsChemoter. – 1993. – Vol. 79. – P. 563-555.464. Somocurcio JG, Sotomayor A, Shin S, et al. Surgery for patients with drugresistant tuberculosis: report of 121 cases receiving community-based treatmentin Lima, Peru. Thorax 2007; 62: 416–21.465. Sreevatsan S. et al. Characterization of rpsL and rrs mutations instreptomycin-resistant Mycobacterium tuberculosis isolates from diversegeographic localities // Antimicrobial Agents and Chemotherapy. – 1996.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
